

**Saturday, 26 September 13.00 – 14.30**

*Personalized Treatment in Advanced ALK+ NSCLC:  
Applying the Science of Targeted Therapy Now and in the Future*

**Educational Objectives**

- To discuss the implications and management of the *EML4-ALK* fusion oncogene in a subset of NSCLC
- To describe ALK-inhibitors in the clinical management of patients with ALK+ NSCLC, including patients with brain metastases
- To utilize patient case studies to understand clinical trial results and the multi-disciplinary approach to the clinical management of advanced ALK+ NSCLC
- To highlight emerging oncogene targets in the treatment of NSCLC, including the latest available data, and outline future promising combination therapy options

**Agenda**

<b>Time</b>	<b>Topic/Activity</b>	<b>Presenter/Participants</b>
<b>13.00 – 13.10</b>	<b>Welcome and Introduction to Personalizing Treatment by Identifying Specific Targets in NSCLC</b> <ul style="list-style-type: none"> <li>• Meeting objectives</li> <li>• Emerging oncogenic targets (<i>KRAS</i>, <i>BRAF</i>, <i>MEK</i>)</li> <li>• Role of immunotherapy in NSCLC with target mutation</li> </ul>	Tony Mok
<b>13.10 – 13.30</b>	<b>ALK+ NSCLC: From Diagnosis to Treatment Options</b> <ul style="list-style-type: none"> <li>• Distinct features of ALK+ NSCLC</li> <li>• Managing advanced ALK+ NSCLC with targeted treatment</li> <li>• Incidence of brain metastases and impact on prognosis</li> <li>• Second-generation ALK inhibitors: Assessing the data</li> </ul>	Johan Vansteenkiste
<b>13.30 – 13.45</b>	<b>Interactive Panel Debate</b> <ul style="list-style-type: none"> <li>• Patient case discussion: 44-year old male, non-smoker, ALK+ NSCLC, disease progression after first-line ALK-inhibitor treatment (5 min)</li> <li>• Q&amp;A (10 min)</li> </ul>	Panel
<b>13.45 – 14.05</b>	<b>Optimizing ALK+ NSCLC Management</b> <ul style="list-style-type: none"> <li>• Mechanisms of resistance to first-generation ALK-inhibitors</li> <li>• Addressing disease progression in ALK+ NSCLC</li> <li>• Sequence of agents in ALK+ NSCLC</li> <li>• Clinical management of brain metastases</li> <li>• Managing adverse events</li> </ul>	Filippo de Marinis
<b>14.05 – 14.15</b>	<b>Interactive Panel Debate</b> <ul style="list-style-type: none"> <li>• Patient case discussion: 58-year old female, non-smoker, ALK+ NSCLC, disease progression after chemotherapy; brain metastases (5 min)</li> </ul>	Panel

ECC/ESMO 2015, Vienna  
Novartis Lung Cancer Satellite Symposium

Saturday, 26 September 13.00 – 14.30

- Q&A (5 min)

14.15 – 14:30

**Concluding Remarks and Future Perspectives**

Tony Mok

- Targeted therapies beyond ALK
  - Data on emerging oncogenic targets: *KRAS*, *BRAF*, *MEK*
  - Combined inhibition: latest evidence
-